The S/Co value was calculated as the sample OD divided by the cut-off value. binding capacity of 0.96 and affinity of 113?family has IL4R a single stranded positive-sense RNA genome of approximately 9.6?kb. It encodes a single open reading frame of about 3000 amino acid polyprotein which is usually then cleaved by viral and cellular proteases into mature viral proteins: core protein, envelope glycoproteins (E1 and E2), and six nonstructural proteins (NS2, NS3, NS4a, NS4b, NS5a, and NS5b) [5, 6]. The HCV core protein, as well as the nonstructural proteins NS3 and NS5, has been commonly used as a coating antigen for the commercial ELISA diagnostic products (MUREX, MP, ORTHO, INNOTEST, and GBC) [7, 8]. Nonetheless, HCV core is the major coating antigen for detecting the early-phase contamination before seroconversion . HCV core protein consists of three domains: a basic and hydrophilic region (domain name I; WWL70 residues 1 to 118), a C terminal hydrophobic domain name (domain name II; residues 119 to 173), and the last hydrophobic signal sequence (domain name III; residues 174 to 191). Domain name I that includes numerous positively charged amino acids involved in RNA binding contains the immunodominant antigenic sites . The recombinant core protein has been expressed in COS cells, insect cells, translation system . Most of the recombinant core proteins were expressed in inclusion body and purified under denaturing condition [12C14]. The inclusion body form is beneficial for industrial production; however, a proper antigenic property which could represent the infection form is still lacking. In this study, random mutagenesis was employed to generate a library of recombinant clones to express random mutants of HCV core domain name I. For efficient screening of this library, a reverse-ELISA was established as shown in WWL70 Physique S1. Five of 616 mutants were selected and overexpressed in and the recombinant proteins all form inclusion bodies. The insoluble proteins dissolved in urea were then purified and refolded by stepwise dialysis to remove urea. Finally, kinetic analysis of the purified proteins was performed and the results were compared for a possible mechanism of the antigenicity enhancement. 2. Materials WWL70 and Methods 2.1. Chemicals All reagents used in the study were of analytical grade and purchased from Sigma or Merck. 2.2. Bacterial Strains TheE. coli B F?was then screened by its antigenicities. 2.6. Antigenicity Screening by Reverse-ELISA A single colony on LBA plate was selected and inoculated into 200?After washing away the unbound /em proteins using 10 column volumes of buffer B, the target protein was eluted using a linear gradient of imidazole concentration from 5?mM to 100?mM. The purified HCV core antigen was pooled as unfolded antigen and stored at 4C before use. 2.8. Refolding of the Unfolded HCV Core via Dialysis The unfolded HCV core antigen was dialyzed against 50 volumes of buffer C (20?mM Tris base and 20?mM 2-Mercaptoethanol at pH 7.6) for 8?h at 4C using a molecular-porous membrane tubing (SPECTRUM, MWCO: 6 to 8 8,000). The dialysis was repeated twice, followed by 5 occasions dialysis against buffer D (20?mM Tris base pH 7.6) for 12?hr at 4C. The resulting dialysis answer was centrifuged WWL70 (10,600??g, 60?min, 4C) to remove the insoluble portion. The supernatant made up of the soluble refolded antigen was then subjected to protein concentration determination, SDS-PAGE analysis for the protein homogeneity, and ELISA to evaluate the antibody binding capacity. 2.9. HPLC Performance Purity of the proteins was analyzed using high performance liquid chromatography (HPLC; 600E Multisolvent Delivery System, Waters Corporation, USA) with an Ultra High Resolution SEC column (BioSuite 125, 4? em /em m, Waters Corporation, USA) under 4C. The insoluble proteins were separated and eluted with 0.15?M phosphate buffer (pH 6.8) and 3?M.